GlassScriptPhysician profile
Fernando B Bravo
NPI 1245262104
$10,314.87
in general payments reported to CMS, 2019-2025
35 companies · $28.29 in 2025
The $28.29 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,248 · 2020: $2,432 · 2021: $2,525 · 2022: $1,636 · 2023: $1,262 · 2024: $1,183 · 2025: $28.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,473.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,062.99 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $940.01 | 2019-2024 | Jardiance, Synjardy, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $911.77 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $907.71 | 2019-2024 | Ubrelvy, Linzess, Qulipta |
| Lilly USA, LLC | $806.40 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $765.77 | 2019-2024 | Repatha, Otezla, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $708.08 | 2019-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $587.33 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $558.50 | 2019-2023 | Xifaxan |
| Pfizer INC. | $503.54 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $346.78 | 2019-2023 | Verquvo, Belsomra |
| Astellas Pharma US INC | $280.00 | 2019-2022 | |
| Horizon Therapeutics Plc | $239.35 | 2020-2022 | |
| Almatica Pharma LLC | $204.34 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $199.16 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $151.25 | 2022-2023 | Auvelity |
| Arbor Pharmaceuticals, INC. | $145.13 | 2019-2021 | |
| Glaxosmithkline, LLC. | $142.80 | 2020-2024 | Shingrix |
| Allergan, INC. | $137.04 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $115.61 | 2020-2024 | Rexulti |
| Lundbeck LLC | $104.30 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $99.98 | 2019-2023 | Eliquis |
| Assertio Therapeutics, INC. | $77.26 | 2019-2020 | |
| Eisai INC. | $49.38 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.66 | 2022 | |
| Topcon Healthcare Solutions, INC. | $34.46 | 2020 | |
| Ironwood Pharmaceuticals, INC | $33.31 | 2022-2023 | Linzess |
| Novartis Pharmaceuticals Corporation | $24.89 | 2020 | |
| Abbott Laboratories | $23.99 | 2022 | |
| Ardelyx, INC. | $22.12 | 2024 | Ibsrela |
| Medicure Pharma INC. | $22.11 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.92 | 2021 | |
| Avanir Pharmaceuticals, INC. | $17.15 | 2019 | |
| Nabriva Therapeutics, Plc | $16.51 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Bravo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.